ORLANDO, Fla. & WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) announced that data from its Phase 3 RAMP-1 (real time assessment of myocardial perfusion) and RAMP-2 clinical trials of Imagify™ (Perflubutane Polymer Microspheres) for Injectable Suspension were presented today at the annual American Heart Association meeting in Orlando, Florida. The results from these international multi-center trials indicate that Imagify Perfusion Stress Echo is an effective and well-tolerated, minimally invasive approach to evaluating chest pain patients at risk for heart attack.
